MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Clinal comprehensive Next-gen gene panel for Parkinson’s Disease

Z. Niu, E. Lauer, S. Roellinger, L. Hasadsri, O. Ross, R. Savica (Rochester, USA)

Meeting: 2023 International Congress

Abstract Number: 1099

Keywords: Parkinson’s, Parkinsonism

Category: Parkinson's Disease: Genetics

Objective: Parkinson’s disease (PD) is a neurodegenerative disorder that affects millions of people. There is growing evidence on both gene mutations associated with PD and genetic factors contributing to PD risk. The object of this study is to design, validate, and implement a clinical comprehensive NextGen (NGS) gene panel for PD diagnosis.

Background: The number of known monogenic causal genes for PD has increased significantly, similarly to susceptibility genes. The advancement of NGS technology opened the avenue for efficient genetic testing. However, most genetic PD tests focus on classic PD genes and often consider a positive family history before testing. To bring up-to-date genetics to PD clinician’s toolbox, we developed a 94-gene Parkinson Disease Panel to evaluate both inherited and sporadic forms of PD as a comprehensive clinical test.

Method: A multidisciplinary team of experts in Mayo Clinic Neurology, Genetics, and Laboratory Medicine and Pathology collaborated to develop this PD gene panel. We identified genes associated with PD based on primary literature, clinical guideline, and expert input. Upon expert consensus, 94 genes were included for clinical testing, doubling the gene counts over most existing tests. Both public and private mutation databases, with >100,000 entries, were considered for technical evaluation by NGS method. We also evaluated challenging mutations and common disease-causing mutations, some of which have higher frequency in certain populations.

Technical performance of this 94 gene Parkinson Disease Panel is validated to detect 95% of deletions up to 75base pairs (bp) and insertions up to 47bp (including certain mobile element), and high-resolution copy number analysis to single and multi-exon events. All detected variants are reported according to American College of Medical Genetics and Genomics (ACMG) recommendations.

Results: Overall, the launch of a 94 gene Parkinson Disease Panel represents a significant step towards personalized medicine for PD patients. With streamlined laboratory workflows and optimized clinical turnaround time, this test showed initial success in PD evaluation.

Conclusion: Incorporating gene panels into PD management will improve patient outcomes and enhance our understanding of the disease, as the interplay between genetic and nongenetic factors. Developing this clinical comprehensive PD panel also serves as a platform for incorporating new discoveries into clinical practice timely.

To cite this abstract in AMA style:

Z. Niu, E. Lauer, S. Roellinger, L. Hasadsri, O. Ross, R. Savica. Clinal comprehensive Next-gen gene panel for Parkinson’s Disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/clinal-comprehensive-next-gen-gene-panel-for-parkinsons-disease/. Accessed September 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/clinal-comprehensive-next-gen-gene-panel-for-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Advanced Search
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley